MIRMMirum Pharmaceuticals, Inc.
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+11% of shares).
Rangebound, no clear trend. Price is −10% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How MIRM is trading
Mirum Pharmaceuticals, Inc. is +16% over the past year while the S&P 500 is +18%: 2.7 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −9.8%
vs 200-day average · below trend, but not far
- RSI (14)
- 35
RSI (14) · neutral
- Below its 52-week high
- 30%
Below its 52-week high
Details›
- Last close2026-10-09
- $85.96
- 1 monthS&P 500 +2.7%
- −15%
- 1 yearS&P 500 +18%
- +16%
- 5 yearsS&P 500 +88%
- +382%
- vs 50-day average$95.58
- −10%
- 52-week high
- $122.04
- 52-week low
- $64.10
- Annualised volatility
- 43%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$5.4M
| Year | Return |
|---|---|
| 2026 (year to date) | +8.8% |
| 2025 | +91% |
| 2024 | +40% |
| 2023 | +51% |
| 2022 | +22% |
| 2021 | −8.6% |
| 2020 | −29% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 7 | 5 of 7 | +6.6% |
| Feb | 7 | 5 of 7 | +3.8% |
| Mar | 7 | 3 of 7 | −4.3% |
| Apr | 7 | 4 of 7 | +5.8% |
| May | 7 | 2 of 7 | −2.5% |
| Jun | 7 | 5 of 7 | +11% |
| Jul | 7 | 4 of 7 | +5.9% |
| Aug | 8 | 5 of 8 | +7.8% |
| Sep | 8 | 2 of 8 | −5.4% |
| Oct | 8 | 2 of 8 | −9.3% |
| Nov | 7 | 5 of 7 | +8.5% |
| Dec | 7 | 4 of 7 | +32% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.